西格列汀联合门冬胰岛素30治疗肥胖型2型糖尿病患者的临床效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (448 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study clinical effect of Sitagliptin combined with Insulin Aspart 30 in the treatment of obese type 2 diabetes. Methods Eighty cases of obese type 2 diabetes patients who were admitted to the First People′s Hospital of Hefei from March 2018 to September 2019 were selected for this study. They were divided into the control group and the observation group by random number table method, with 40 cases in each group. The control group was given Insulin Aspart 30, and the observation group was treated with Sitagliptin on the basis of the control group, and both groups were treated continuously for three months. The clinical efficacy, the changes in blood lipids(total cholesterol [TC], triacylglycerol [TG], high density lipoprotein-cholesterol [HDL-C], low density lipoprotein-cholesterol [LDL-C]), blood glucose (fasting blood glucose [FBG], 2-hour postprandial blood glucose [2hPBG], glycated hemoglobin [HbA1c]), body mass index (BMI), uric acid (UA), hypersensitive C-reactive protein (hs-CRP) before and after treatment and adverse reactions were compared between the two groups. Results After treatment, the total effective rate of the observation group (95.00%) was higher than that of the control group (80.00%), the difference was statistically significant (P ＜ 0.05). After treatment, TC, TG and LDL-C levels decreased with HDL-C levels increased in both groups compared with those before treatment, and TC, TG and LDL-C levels in the observation group after treatment were lower than those in the control group, HDL-C level was higher than that in the control group, the differences were statistically significant (P ＜ 0.05). After treatment, FBG, 2hPBG and HbA1c levels decreased in both groups compared with those before treatment, and FBG, 2hPBG and HbA1c levels in the observation group were lower than those in the control group, the differences were statistically significant (P ＜ 0.05). After treatment, BMI, UA, hs-CRP levels decreased in both groups compared with those before treatment, and BMI, UA, hs-CRP levels of the observation group were lower than those of the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the adverse reactions between the two groups (P ＞ 0.05). Conclusion The clinical efficacy of Sitagliptin combined with Insulin Aspart 30 in the treatment of obese type 2 diabetes is outstanding, and the patient′s blood lipid and blood glucose levels are significantly improved, which can effectively reduce the BMI, and it is worthy of clinical promotion.

Key words： Obese type 2 diabetes Sitagliptin Insulin Aspart 30 Blood glucose Blood lipid Body mass index

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Jie LYU Fang WANG Guojuan MA Weiqing▲

Cite this article:

LIU Jie LYU Fang WANG Guojuan MA Weiqing▲. Clinical effect of Sitagliptin combined with Insulin Aspart 30 in the treatment of obese type 2 diabetes[J]. 中国医药导报, 2020, 17(24): 75-78.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I24/75

[1] 陆玲玲，刘雅.人体学指标预测2型糖尿病发病风险的研究进展[J].四川医学，2019，40（4）：435-438.
[2] 杨帆，崔静，苑东敏，等.中年人群肥胖指标与新诊2型糖尿病的关联研究[J].现代预防医学，2019，46（10）：1795-1800.
[3] 李伟，张晨鑫，王玲，等. 2型糖尿病合并肥胖患者腹部脂肪分布与胰岛素抵抗的相关性研究[J].重庆医学，2017， 46（26）：3632-3634.
[4] Rizzo M，Al-Busaidi N，Rizvi AA. Dapagliflozin therapy in type-2 diabetes：Current knowledge and future perspectives [J]. Expert Opin Pharmaco，2014，16（3）：1-4.
[5] 邹金生.门冬胰岛素30联合二甲双胍治疗老年初诊2型糖尿病疗效观察[J].糖尿病新世界，2018，21（3）：50-51.
[6] 张雪莲，崔玲，罗斌，等.门冬胰岛素30与预混人胰岛素治疗中国2型糖尿病患者的Meta分析[J].中国糖尿病杂志，2018，26（9）：25-34.
[7] 刘阳，杨静，任毅，等.磷酸西格列汀联合二甲双胍治疗2型糖尿病的临床疗效观察[J].中西医结合心脑血管病杂志，2018，16（12）：1725-1727.
[8] 吴金婵，陈娟，冯光球.二甲双胍联合西格列汀或瑞格列奈治疗肥胖2型糖尿病患者的效果比较[J].中国医药，2019，14（5）：87-90.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：34-86.
[10] 贾伟平，陈莉明.中国血糖监测临床应用指南（2015年版）[J].中华糖尿病杂志，2015，7（10）：603-613.
[11] Jha S，Panda M，Kumar S，et al. Psychological insulin resistance in patients with type 2 diabetes [J]. J Assoc Physicians India，2015，63（7）：33-39.
[12] 蔡晓凌，杨文嘉，高学营，等.中国2型糖尿病患者胰岛素剂量的荟萃分析[J].中国糖尿病杂志，2016，24（6）：490-507.
[13] 阚卫军，李清，刘红星，等.2型糖尿病治疗新进展[J].山西医药杂志，2018，47（13）：1547-1550.
[14] Wang J，Yan R，Wen J，et al. Association of lower body mass index with increased glycemic variability in patients with newly diagnosed type 2 diabetes：a cross-sectional study in China [J]. Oncotarget，2017，8（42）：73133-73143.
[15] 李蕊，金晓娜，张党锋.维格列汀联合门冬胰岛素30注射液对肥胖型2型糖尿病患者胰岛β细胞功能及血清糖化血红蛋白水平的影响[J].武警医学，2019，30（6）：499-502.
[16] 钱程，王铮，王丽云，等.沙格列汀联合门冬胰岛素30治疗超重2型糖尿病患者的疗效分析[J].现代医药卫生，2018，34（24）：3817-3819.
[17] 熊英，马红娥，刘宝堂，等.门冬胰岛素对Ⅱ型糖尿病患者心血管病变的影响[J].海南医学，2018，29（19）：34-37.
[18] 陈红霞，史婷婷，袁群，等.西格列汀与二甲双胍联用治疗老年2型糖尿病的疗治效观察[J].微循环学杂志，2019， 29（1）：22-26.
[19] 王丹阳，苗润培，熊敏，等.西格列汀的作用机制和二肽基肽酶4抑制剂对肾脏作用的临床研究进展[J].中国医刊，2018，53（5）：24-27.
[20] 李颖，马维青，刘尚全.西格列汀在预混胰岛素疗效不佳的2型糖尿病患者中的应用效果[J].广西医学，2017， 39（12）：1852-1854.
[21] 陈赟，何瑶，马维青，等.西格列汀联合二甲双胍治疗腹型肥胖2型糖尿病的临床效果及安全性[J].中国医药，2018，13（4）：545-549.
[22] 郝兆虎，邵海琳，黄霄，等.达格列净与西格列汀对胰岛素控制不佳的超重及肥胖2型糖尿病患者的疗效观察[J].中华糖尿病杂志，2019，11（9）：592-596.
[23] 刘萍，庄向华，徐敏，等.西格列汀在糖尿病周围神经病变中的效果[J].山东大学学报：医学版，2019，57（3）：64-68.
[24] 李立，张朝云，卢姗，等.利格列汀联合胰岛素治疗2型糖尿病合并肾病的临床效果[J].中国医药导报，2020， 17（17）：173-176.
[25] 孙利军.西格列汀联合门冬胰岛素30注射液对初诊2型糖尿病患者血糖控制及氧化应激反应的影响[J].现代医药卫生，2019，35（9）：1387-1389.
[26] 李慧聪.西格列汀联合门冬胰岛素对老年2型糖尿病患者血糖控制及血脂水平的影响[J].北方药学，2019， 16（1）：110-111.